Close menu

November 15th, 2021 | 10:50 CET

Valneva, XPhyto, NanoRepro - Here we go again

  • Biotechnology
Photo credits:

Although around 67.4% of the population in Germany is already fully vaccinated, the infection figures are rising to unprecedented heights. The fourth wave with the highly contagious Delta variant is rolling across the republic. This development must be stopped as quickly as possible. In addition to booster vaccinations, politicians are therefore reintroducing citizen testing as a tool against the spread. For diagnostics companies and providers of rapid tests, this means a boom and further increases in earnings, likely to be reflected in stock market valuations in the near future.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: VALNEVA SE EO -_15 | FR0004056851 , XPHYTO THERAPEUTICS | CA98421R1055 , NANOREPRO AG | DE0006577109

Table of contents:

    Fourth wave at NanoRepro

    NanoRepro AG, based in Marburg an der Lahn, Germany, is again experiencing a significant increase in demand for reliable rapid tests due to the renewed sharp rise in SARS-CoV-2 infection figures. The stock market already celebrated the special economic situation last week with substantial increases. From a low of EUR 7.0, the share price rose to a weekly high of EUR 9.50 by Friday evening. Investors were also increasingly willing to buy after the close of trading. No wonder, after all, the quick test shelves at the discounters were literally swept empty. Therefore, it should come as no surprise if this highly volatile stock again attacks the highs for the year above EUR 20. There is unlikely to be an end to the demand for rapid tests until the second quarter of next year.

    Meanwhile, the diagnostics company reports that due diligence on the potential integration of Viromed Group businesses is expected to be completed by the annual general meeting on December 22, 2021. NanoRepro AG is using the process, which is still ongoing due to the complexity of the Viromed Group's three business areas, VitaLab, terraplasma and vitabook, to examine the option of meaningfully supplementing or expanding its product portfolio in order to be able to continue the Company's positive development in the next few years after the COVID-19 pandemic and the demand for corresponding rapid tests have subsided. The stock is likely to remain in the spotlight in the coming weeks.

    XPhyto with pioneering work

    The demand for PCR or rapid tests could rise to new, unimagined heights in the coming months. Profiting from the estimated USD 40 billion rapid test market is likely to be life science accelerator XPhyto. The Company focuses on investing in next-generation drug delivery, diagnostics and new pharmaceutical compounds. The Canadians are in the right place at the right time with the Covid-ID Lab developed in collaboration with Stuttgart-based 3a-diagnostics GmbH, in which XPhyto already has an option to buy.

    The advantage of the COVID-19 RT-PCR test system "Covid-ID Lab" is that results are delivered within 20 to 25 minutes, as prior RNA extraction as part of sample preparation is not required here. That puts the product between disposable antigen tests and centralized, automated PCR systems. Especially at airports, medical care facilities and pharmacies, the product is likely to be used preferentially.

    In the next growth and development phase, Prof. Dr. Thomas Beckert will be appointed Managing Director of XP Diagnostics GmbH to lead XPhyto's business in Germany and accompany the integration of 3a-diagnostics GmbH. In addition, XPhyto will launch a non-brokered private placement and unsecured convertible notes. As part of the offering, the Company has agreed to a non-brokered private placement of up to 5,000,000 common shares at a price of CAD 1.00 per share for gross proceeds of up to CAD 5 million. In addition, the Company discussed the issuance of up to CAD 2.5 million of 8% unsecured convertible debentures and 2 million common share purchase warrants. The proceeds are to be used for research and development, inventory purchases, general working capital purposes and the closing of the announced acquisition of 3a-diagnostics.

    XPhyto is developing a broad range of diagnostics and active pharmaceutical ingredients, including infectious disease and oral health tests, and standardizing new active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids, in addition to the Corona test discussed. Given the correction in recent months and strong demand for testing in the wake of SARS-CoV 2, investors should take a closer look at this Company.

    Is Valneva reaching a new target group?

    Good news for the unvaccinated, who were previously skeptical about the administration of a Corona vaccine and, in particular, strongly opposed mRNA vaccines from BioNTech/Pfizer and Moderna. The reluctance to administer such a vaccine is the belief that such vaccines could alter the genetic makeup of cells and cause damage. In addition, the uncertainty of the preparation due to its rapid approval and novelty was criticized from the same corner.

    The introduction of the dead vaccine from the Austrian-French Company Valneva should make it easier for those who are undecided to go to the vaccination center or family doctor. Thus, the European Union may purchase up to 60 million doses of a possible Corona vaccine. The EU Commission formally approved a contract for 27 million doses next year. Another 33 million doses can be purchased if desired in 2023, according to the Brussels-based agency. However, approval is still a prerequisite, the procedures for which are to be started soon. In Great Britain, the approval process has already begun, and approval is expected this year in the best-case scenario.

    While the stock market celebrated the news with the most significant price jump in the still young stock market history of Valneva, the analysts of First Berlin put on the euphoria brakes. They calculate a sales explosion from currently EUR 103.1 million to EUR 805.9 million in 2022. However, the experts' model includes the recently completed capital increase. Accordingly, First Berlin lowers the price target of Valneva to EUR 23.40 and assigns the rating "add".

    The fourth wave is rolling through Germany. In addition to initial and booster vaccinations, reliable tests in particular help to counteract the negative development. NanoRepro and XPhyto are likely to benefit from increased demand for tests. Valneva could shake up the group of vaccination skeptics.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by Juliane Zielonka on May 12th, 2022 | 13:07 CEST

    Cardiol Therapeutics, Tesla, Bayer AG - Instead of trading chronically overvalued shares, treat the chronically ill instead

    • Biotechnology

    No sooner does the US government under Biden seek to influence the Supreme Court in the Monsanto case than the Bayer share slides 7%. But is this share price slide justified? Bayer AG has made provisions for the possible ruling in June and set aside reserves for chronic diseases. Chronic diseases are also a focus of Cardiol Therapeutics. According to the World Health Organization (WHO), the prevalence of chronic diseases increased by 57% worldwide by 2020. Cardiol focuses on heart health in this regard. The share stands at about EUR 1.12 and is seen by analysts at an average of about EUR 7. Meanwhile, Tesla investors are currently experiencing what overvalued shares can do to their portfolios. Their CEO is speculating that he will no longer accept new customers. Why? You can read about it here...


    Commented by Fabian Lorenz on May 12th, 2022 | 11:12 CEST

    BioNTech, BYD and Desert Gold: Shares for the rebound

    • Gold
    • Electromobility
    • Biotechnology

    Is the rebound coming? After the heavy price losses of recent days and weeks, the market seems ripe for a countermovement. However, this would require a little more volume in the market. But then, especially companies that have not disappointed operationally should profit. BioNTech, for example, belongs to this group. The Company has published convincing figures, and analysts see up to 50% price potential. BYD's share price should also pick up speed again. Finally, the rapid shift to electric pureplay seems to be succeeding and HSBC has raised the price target. Gold was not a safe haven in the current correction. But it is worth looking at bombed-out stocks here as well. Desert Gold Ventures is one of them. The explorer has started a new drill program and secured financing.


    Commented by Juliane Zielonka on May 10th, 2022 | 12:38 CEST

    Biotech stocks: Defence Therapeutics, BioNTech, BASF - Advantage through platform technology

    • Biotechnology

    Large corporations such as BASF were previously considered safe portfolio investments. But the war in Ukraine is throwing a spanner in the works. Force majeure, such as war, can cause deals to fall through without the responsibility of the companies involved. How should investors react now? Which portfolio strategy can keep up with the high volatility of the markets? Newcomers like BioNTech face oversupply and have to accept shortages. A focus on emerging markets seems to be the solution for their growth strategy. But there are subtle differences in the vaccines business, as Defence Therapeutics proves.